← Leaderboards
Katherine Marie Aird
Wistar Institute
$5,557,021
Attributed
$7,777,196
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,777,196 · 6
By mechanism
R01$4,215,842 · 3
R37$2,634,159 · 1
R00$697,167 · 1
K99$230,028 · 1
Top collaborators
- Nathaniel W. Snyder8 shared
- Raquel Buj Gomez2 shared
- Nadine Hempel2 shared
Most similar at Wistar Institute
Same institution · by research overlap
- Ashani T Weeraratna$9,422,460
- Vito William Rebecca$2,085,689
- Maureen E Murphy$37,408,887
- Chengyu Liang$16,417,485
- Dorothee M Herlyn$8,362,969
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingResistanceMolecularStandard Of CareMalignant NeoplasmsTreatment ResponsePathway InteractionsCancer CellCellsTumorigenesisPublishingMetabolicInsightTherapy OutcomeEventMetabolismOncogenesFutureNovel Therapeutic InterventionTumorPatient PopulationTreatment StrategyNew Therapeutic TargetCell Cycle
Grant awards (21)
Investigating p16 Loss in Pro-tumorigenic Metabolism$874,892
R37 · FY2025 · CA · contact PI
Acylcarnitine Metabolism in Ovarian Cancer Chemoresistance$686,654
R01 · FY2025 · CA · contact PI
Cell intrinsic and extrinsic effects of zinc metabolism in therapy resistant melanoma$400,461
R01 · FY2025 · CA · contact PI
Metabolic and epigenetic reprogramming in cyclin E high ovarian cancer$308,991
R01 · FY2025 · CA · contact PI
Cell intrinsic and extrinsic effects of zinc metabolism in therapy resistant melanoma$273,065
R01 · FY2025 · CA · contact PI
Metabolic and epigenetic reprogramming in cyclin E high ovarian cancer$212,508
R01 · FY2025 · CA · contact PI
Metabolic and epigenetic reprogramming in cyclin E high ovarian cancer$504,676
R01 · FY2024 · CA · contact PI
Investigating p16 Loss in Pro-tumorigenic Metabolism$333,898
R37 · FY2024 · CA · contact PI
Metabolic and epigenetic reprogramming in cyclin E high ovarian cancer$198,750
R01 · FY2024 · CA · contact PI
Metabolic and epigenetic reprogramming in cyclin E high ovarian cancer$523,359
R01 · FY2023 · CA · contact PI
Investigating p16 Loss in Pro-tumorigenic Metabolism$346,730
R37 · FY2023 · CA · contact PI
Metabolic and epigenetic reprogramming in cyclin E high ovarian cancer$533,073
R01 · FY2022 · CA · contact PI
Investigating p16 Loss in Pro-tumorigenic Metabolism$355,915
R37 · FY2022 · CA · contact PI
Metabolic and epigenetic reprogramming in cyclin E high ovarian cancer$574,305
R01 · FY2021 · CA · contact PI
Investigating p16 Loss in Pro-tumorigenic Metabolism$352,278
R37 · FY2021 · CA · contact PI
Investigating p16 Loss in Pro-tumorigenic Metabolism$370,446
R37 · FY2020 · CA · contact PI
Nucleotide Metabolism in Senescence and Platinum Resistance of Ovarian Cancer$237,702
R00 · FY2019 · CA · contact PI
Nucleotide Metabolism in Senescence and Platinum Resistance of Ovarian Cancer$210,465
R00 · FY2018 · CA · contact PI
Nucleotide Metabolism in Senescence and Platinum Resistance of Ovarian Cancer$249,000
R00 · FY2017 · CA · contact PI
Nucleotide Metabolism in Senescence and Platinum Resistance of Ovarian Cancer$115,014
K99 · FY2016 · CA · contact PI
Nucleotide Metabolism in Senescence and Platinum Resistance of Ovarian Cancer$115,014
K99 · FY2015 · CA · contact PI